Eli Lilly LLY Europe — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eli Lilly's europe — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eli Lilly's europe — revenue?
- Eli Lilly (LLY) reported europe — revenue of $3.65B in Q1 2026.
- How has Eli Lilly's europe — revenue changed year-over-year?
- Eli Lilly's europe — revenue increased by 52.6% year-over-year, from $2.39B to $3.65B.
- What is the long-term trend for Eli Lilly's europe — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's europe — revenue has grown at a 24.7% compound annual growth rate (CAGR), from $4.78B to $11.56B.
- What does europe — revenue mean?
- This metric represents the total gross sales generated from pharmaceutical products sold within the European geographic market. It reflects the company's commercial footprint, market penetration, and demand for its therapeutic portfolio across European healthcare systems. Fluctuations in this figure are driven by product launches, regulatory pricing adjustments, and competitive dynamics within the region.